Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
An In-depth Analysis of acetaminophen/butalbital/caffeine's R&D Progress
11 October 2023
This article summarized the latest R&D progress of acetaminophen/butalbital/caffeine, the Mechanism of Action for acetaminophen/butalbital/caffeine, and the drug target R&D trends for acetaminophen/butalbital/caffeine.
Advanced Tech.
6 min read
New Hope for Solid Tumor Treatment: TIL Therapy
11 October 2023
TIL therapy uses the patient's own immune cells from the solid tumor microenvironment to kill tumor cells.
Drug Insights
5 min read
carglumic acid: Detailed Review of its Transformative R&D Success
11 October 2023
This article summarized the latest R&D progress of carglumic acid, the Mechanism of Action for carglumic acid, and the drug target R&D trends for carglumic acid.
Latest Hotspot
3 min read
IMUNON Announces Data from Phase 1/2 OVATION 2 Trial for Late-Stage Ovarian Cancer
11 October 2023
IMUNON released preliminary PFS and OS statistics related to IMNN-001 from its Phase 1/2 OVATION 2 Investigation.
Drug Insights
4 min read
Regadenoson: Detailed Review of its Transformative R&D Success
11 October 2023
This article summarized the latest R&D progress of Regadenoson, the Mechanism of Action for Regadenoson, and the drug target R&D trends for Regadenoson.
Advanced Tech.
8 min read
The Multifunctional Novel Products of DNA Recombinant Technology: Fusion Protein
11 October 2023
Fusion protein technology is a purposeful gene fusion and protein expression method to obtain large amounts of standard fusion proteins.
Drug Insights
4 min read
Revefenacin Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
11 October 2023
This article summarized the latest R&D progress of Revefenacin, the Mechanism of Action for Revefenacin, and the drug target R&D trends for Revefenacin.
Latest Hotspot
3 min read
Structure Therapeutics reports outcomes from the Phase 1b clinical study of GSBR-1290
11 October 2023
Structure Therapeutics has revealed encouraging results from its Phase 1b incremental dose study of its exclusive oral GLP-1 receptor agonist, GSBR-1290, in overweight or obese individuals.
Drug Insights
4 min read
Unleashing the Power of Risedronate sodium: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
11 October 2023
This article summarized the latest R&D progress of Risedronate sodium, the Mechanism of Action for Risedronate sodium, and the drug target R&D trends for Risedronate sodium.
Advanced Tech.
6 min read
AstraZeneca reports Phase I clinical trial of inhaled JAK1 inhibitor AZD4604
11 October 2023
Recently, AstraZeneca published in JMC, detailing the development of the inhaled JAK1 inhibitor AZD4604.
Drug Insights
4 min read
A Comprehensive Review of Roxadustat's R&D Innovations and Drug Target Mechanism
10 October 2023
This article summarized the latest R&D progress of Roxadustat, the Mechanism of Action for Roxadustat, and the drug target R&D trends for Roxadustat.
Latest Hotspot
3 min read
Amicus Therapeutics Declares FDA Sanction and Introduction of Novel Therapy for Pompe Disease
10 October 2023
Amicus Therapeutics has confirmed that the U.S. FDA has given the green light to Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules.